Tocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying antirheumatic drugs: real life experience from the TReasure Registry

Basit Öğe Kaydı
dc.authoridGonullu, Emel/0000-0002-6990-4206
dc.contributor.authorKaradag, O.
dc.contributor.authorFarisogullari, B.
dc.contributor.authorYagiz, B.
dc.contributor.authorErden, A.
dc.contributor.authorAdemoglu, Z.
dc.contributor.authorKimyon, G.
dc.contributor.authorBilge, N. S.
dc.date.accessioned2024-10-29T18:00:21Z
dc.date.available2024-10-29T18:00:21Z
dc.date.issued2024
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractObjective To evaluate the retention rate, treatment response and safety of tocilizumab (TCZ) as first-line biologic treatment in rheumatoid arthritis (RA) patients with inadequate response to disease-modifying anti-rheumatic drugs (DMARD-IR). Methods The TReasure Registry is a multicentre, web-based registry of RA and spondyloarthritis patients across Turkey. DMARD-IR RA patients who received TCZ as first-line biologic treatment were included in this registry for efficacy and safety. Demographic and clinical data, treatments, and adverse events were collected. Drug retention rate was estimated using Kaplan-Meier analysis. Results Among 642 RA patients who ever used TCZ, 258 DMARD-IR RA patients (male/female: 18.2%/81.8%, mean age, 54.41 years) received TCZ as first-line biologic. The median disease duration was 97 (range, 60-179) months and the median TCZ treatment duration was 15 (range, 6-28) months. At the 6th and 12th months of TCZ treatment, the decrease in disease activity scores from baseline was significant. The Kaplan-Meier analysis revealed the retention rate of TCZ at the 12th, 24th, 36th, and 60th months as 81.1%, 73.8%, 66.2%, and 63.6%, respectively. Fifty-seven (22%) patients discontinued TCZ; the main reason being primary or secondary inefficacy (n=29). Conclusion Over 80% drug retention rate at 12th month of TCZ treatment in this real-world study was concordant with previously conducted TCZ clinical studies. Significant reductions not only in the disease activity score-28 but also in the simplified disease activity index (SDAI) and clinical disease activity index (CDAI) scores, along with health assessment questionnaire (HAQ) scores, supported the impact of TCZ in RA management with a good safety profile.
dc.identifier.endpage137
dc.identifier.issn0392-856X
dc.identifier.issn1593-098X
dc.identifier.issue1en_US
dc.identifier.pmid37650346
dc.identifier.startpage130
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14986
dc.identifier.volume42
dc.identifier.wosWOS:001163623200028
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherClinical & Exper Rheumatology
dc.relation.ispartofClinical and Experimental Rheumatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjecttocilizumab
dc.subjectbiological drugs
dc.subjectrheumatoid arthritis
dc.subjectdrug retention
dc.subjectreal life data
dc.titleTocilizumab as a first line biologic agent in rheumatoid arthritis patients with inadequate response to disease-modifying antirheumatic drugs: real life experience from the TReasure Registry
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu